DLL4 blockade inhibits tumor growth and reduces tumor-initiating cell frequency - PubMed (original) (raw)
. 2009 Aug 7;5(2):168-77.
doi: 10.1016/j.stem.2009.05.019.
Wan-Ching Yen, Fumiko Axelrod, Jesspreet Basi, Lucas Donigian, Scott Dylla, Maureen Fitch-Bruhns, Sasha Lazetic, In-Kyung Park, Aaron Sato, Sanjeev Satyal, Xinhao Wang, Michael F Clarke, John Lewicki, Austin Gurney
Affiliations
- PMID: 19664991
- DOI: 10.1016/j.stem.2009.05.019
Free article
DLL4 blockade inhibits tumor growth and reduces tumor-initiating cell frequency
Timothy Hoey et al. Cell Stem Cell. 2009.
Free article
Abstract
Previous studies have shown that blocking DLL4 signaling reduced tumor growth by disrupting productive angiogenesis. We developed selective anti-human and anti-mouse DLL4 antibodies to dissect the mechanisms involved by analyzing the contributions of selectively targeting DLL4 in the tumor or in the host vasculature and stroma in xenograft models derived from primary human tumors. We found that each antibody inhibited tumor growth and that the combination of the two antibodies was more effective than either alone. Treatment with anti-human DLL4 inhibited the expression of Notch target genes and reduced proliferation of tumor cells. Furthermore, we found that specifically inhibiting human DLL4 in the tumor, either alone or in combination with the chemotherapeutic agent irinotecan, reduced cancer stem cell frequency, as shown by flow cytometric and in vivo tumorigenicity studies.
Comment in
- Molecular targeting of cancer stem cells.
Gupta R, Vyas P, Enver T. Gupta R, et al. Cell Stem Cell. 2009 Aug 7;5(2):125-6. doi: 10.1016/j.stem.2009.07.006. Cell Stem Cell. 2009. PMID: 19664981
Similar articles
- Dll4 Blockade in Stromal Cells Mediates Antitumor Effects in Preclinical Models of Ovarian Cancer.
Kuhnert F, Chen G, Coetzee S, Thambi N, Hickey C, Shan J, Kovalenko P, Noguera-Troise I, Smith E, Fairhurst J, Andreev J, Kirshner JR, Papadopoulos N, Thurston G. Kuhnert F, et al. Cancer Res. 2015 Oct 1;75(19):4086-96. doi: 10.1158/0008-5472.CAN-14-3773. Epub 2015 Sep 16. Cancer Res. 2015. PMID: 26377940 - Anti-DLL4 inhibits growth and reduces tumor-initiating cell frequency in colorectal tumors with oncogenic KRAS mutations.
Fischer M, Yen WC, Kapoun AM, Wang M, O'Young G, Lewicki J, Gurney A, Hoey T. Fischer M, et al. Cancer Res. 2011 Mar 1;71(5):1520-5. doi: 10.1158/0008-5472.CAN-10-2817. Epub 2010 Dec 30. Cancer Res. 2011. PMID: 21193546 - MMGZ01, an anti-DLL4 monoclonal antibody, promotes nonfunctional vessels and inhibits breast tumor growth.
Xu Z, Wang Z, Jia X, Wang L, Chen Z, Wang S, Wang M, Zhang J, Wu M. Xu Z, et al. Cancer Lett. 2016 Mar 1;372(1):118-27. doi: 10.1016/j.canlet.2015.12.025. Epub 2015 Dec 29. Cancer Lett. 2016. PMID: 26739060 - New pathways and mechanisms regulating and responding to Delta-like ligand 4-Notch signalling in tumour angiogenesis.
Oon CE, Harris AL. Oon CE, et al. Biochem Soc Trans. 2011 Dec;39(6):1612-8. doi: 10.1042/BST20110721. Biochem Soc Trans. 2011. PMID: 22103496 Review. - Monoclonal antibodies against human cancer stem cells.
Naujokat C. Naujokat C. Immunotherapy. 2014;6(3):290-308. doi: 10.2217/imt.14.4. Immunotherapy. 2014. PMID: 24762074 Review.
Cited by
- Cancer-wide in silico analyses using differentially expressed genes demonstrate the functions and clinical relevance of JAG, DLL, and NOTCH.
Kim JY, Hong N, Ham SW, Park S, Seo S, Kim H. Kim JY, et al. PLoS One. 2024 Jul 29;19(7):e0307943. doi: 10.1371/journal.pone.0307943. eCollection 2024. PLoS One. 2024. PMID: 39074091 Free PMC article. - The Prediction of DLL4 as a Prognostic Biomarker in Patients with Gastric Cancer Using Anti-DLL4 Nanobody.
Afzalipour R, Abbasi-Dokht T, Sheikh M, Mohammadlou M, Nili F, Baharlou R. Afzalipour R, et al. J Gastrointest Cancer. 2024 Sep;55(3):1380-1387. doi: 10.1007/s12029-024-01093-9. Epub 2024 Jul 24. J Gastrointest Cancer. 2024. PMID: 39046662 - Ginseng-derived compounds as potential anticancer agents targeting cancer stem cells.
Lee JS, Lee HY. Lee JS, et al. J Ginseng Res. 2024 May;48(3):266-275. doi: 10.1016/j.jgr.2024.03.003. Epub 2024 Mar 12. J Ginseng Res. 2024. PMID: 38707642 Free PMC article. Review. - Colorectal Cancer Stem Cells and Targeted Agents.
Zhao H, Han R, Wang Z, Xian J, Bai X. Zhao H, et al. Pharmaceutics. 2023 Dec 12;15(12):2763. doi: 10.3390/pharmaceutics15122763. Pharmaceutics. 2023. PMID: 38140103 Free PMC article. Review. - Notch receptor/ligand diversity: contribution to colorectal cancer stem cell heterogeneity.
Brisset M, Mehlen P, Meurette O, Hollande F. Brisset M, et al. Front Cell Dev Biol. 2023 Oct 4;11:1231416. doi: 10.3389/fcell.2023.1231416. eCollection 2023. Front Cell Dev Biol. 2023. PMID: 37860822 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials